"Androgens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.
Concept/Terms
Androgens- Androgens
- Androgenic Agents
- Agents, Androgenic
- Androgenic Compounds
- Compounds, Androgenic
- Androgen Receptor Agonists
- Agonists, Androgen Receptor
- Receptor Agonists, Androgen
Androgen Effect- Androgen Effect
- Effect, Androgen
- Androgen Effects
- Effects, Androgen
Below are MeSH descriptors whose meaning is more general than "Androgens".
Below are MeSH descriptors whose meaning is more specific than "Androgens".
This graph shows the total number of publications written about "Androgens" by people in Harvard Catalyst Profiles by year, and whether "Androgens" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 4 | 5 |
| 1995 | 3 | 1 | 4 |
| 1996 | 4 | 1 | 5 |
| 1997 | 4 | 3 | 7 |
| 1998 | 4 | 4 | 8 |
| 1999 | 11 | 3 | 14 |
| 2000 | 7 | 4 | 11 |
| 2001 | 10 | 3 | 13 |
| 2002 | 9 | 3 | 12 |
| 2003 | 12 | 5 | 17 |
| 2004 | 21 | 9 | 30 |
| 2005 | 11 | 7 | 18 |
| 2006 | 21 | 11 | 32 |
| 2007 | 19 | 6 | 25 |
| 2008 | 18 | 10 | 28 |
| 2009 | 22 | 12 | 34 |
| 2010 | 17 | 8 | 25 |
| 2011 | 10 | 14 | 24 |
| 2012 | 10 | 5 | 15 |
| 2013 | 18 | 13 | 31 |
| 2014 | 14 | 4 | 18 |
| 2015 | 18 | 5 | 23 |
| 2016 | 17 | 12 | 29 |
| 2017 | 20 | 6 | 26 |
| 2018 | 14 | 13 | 27 |
| 2019 | 12 | 10 | 22 |
| 2020 | 14 | 14 | 28 |
| 2021 | 12 | 12 | 24 |
| 2022 | 8 | 23 | 31 |
| 2023 | 4 | 22 | 26 |
| 2024 | 1 | 10 | 11 |
Below are the most recent publications written about "Androgens" by people in Profiles.
-
Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial. BMC Womens Health. 2024 Mar 08; 24(1):167.
-
Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer. Curr Oncol Rep. 2024 Mar; 26(3):299-306.
-
SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis. Carcinogenesis. 2024 02 12; 45(1-2):35-44.
-
Can Extreme Dose Escalation With External Beam Radiation Therapy and Low-Dose-Rate Brachytherapy Boost Obviate the Need for Long-Term Androgen Deprivation Therapy in Patients With High-Risk Localized Prostate Cancer? Int J Radiat Oncol Biol Phys. 2024 Feb 01; 118(2):402-403.
-
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 01; 42(10):1114-1123.
-
Early change in apparent diffusion coefficient as a predictor of response to neoadjuvant androgen deprivation and external beam radiation therapy for intermediate- to high-risk prostate cancer. Clin Radiol. 2024 Apr; 79(4):e607-e615.
-
X-chromosome and kidney function: evidence from a multi-trait genetic analysis of 908,697 individuals reveals sex-specific and sex-differential findings in genes regulated by androgen response elements. Nat Commun. 2024 Jan 18; 15(1):586.
-
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. J Natl Cancer Inst. 2024 01 10; 116(1):115-126.
-
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. Nat Commun. 2024 Jan 02; 15(1):14.
-
Simvastatin Enhances the Radiosensitivity of Androgen-independent Prostate Cancer Cells via Inhibition of RAD51 Expression. Anticancer Res. 2024 Jan; 44(1):93-98.